Phase 2 study results of Ionis’ novel antisense treatment for hereditary angioedema to be presented at ACAAI annual meeting
- Sunday, November 7, 2021, 7:13
- PR Newswire
- Add a comment
CARLSBAD, Calif., Nov. 7, 2021 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, announced today that positive results from the Phase 2 study of its investigational antisense medicine, donidalorsen (formerly IONIS-PKK-LRx), will be presented…
About the Author
admin has written 20652 stories on this site.